| Sep-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Sep-2024 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 0% | 0% | 0% | 0% | 0% |
Indian | 66.24% | 66.25% | 66.25% | 66.25% | 66.25% |
Total Promoter | - | - | - | - | - |
Institutions | 26.43% | 26.36% | 26.35% | 26.28% | 26.22% |
Non-Institutions | 7.31% | 7.37% | 7.38% | 7.45% | 7.51% |
Total Non-Promoter | 33.75% | 33.74% | 33.74% | 33.74% | 33.74% |
Custodian | 0% | 0% | 0% | 0% | 0% |
Total | 100% | 100% | 100% | 100% | 100% |
Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
